Develops first-in-class therapeutics for infertility by modulating endometrial lymphatic vasculature to improve implantation rates and endometrial receptivity. Targets individuals and couples with implantation failure and reproductive clinicians, advancing a lymphatic-biology drug platform through translational preclinical models.